Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
“Young researchers such as myself…can provide a new perspective and contribute to the conversation for a cure,” says Chidera Ejikeme.
By altering the components of the vaccine regimen, researchers drove promising antibody and immune-cell responses.
Calling all U.S. cisgender gay and bi men and trans and gender nonconforming people at risk for the virus.
The ASCENT trial found that the vaccine regimen that was advanced to the forthcoming Mosaico trial prompted a strong immune response.
The Mosaico study will enroll gay and bisexual men and transgender people at significant risk for the virus.
Investigators led by Scripps Research will study vaccines that coax the immune system into creating antibodies that protect against HIV.
Federal researchers describe two paths to a vaccine—and one of them uses high-tech computers to design a vaccine candidate!
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against HIV.
A new HIV vaccine prompts powerful antibody response in animals.
A better understanding of the three-part Env protein may help in the design of more effective vaccine candidates.
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against the virus.
Researchers have found a way of stabilizing a shape-shifting viral protein so as to promote a greater antibody response.
The Global HIV Vaccine Enterprise hopes to hasten the development of a safe and effective vaccine against the virus.
The Campbell Foundation’s latest grant funds research into the RV144 trial in Thailand, which showed 31 percent protection against HIV.
NIH researchers have prompted animals to develop broadly neutralizing antibodies against the virus; an early human trial is in the works.
Nope. According to this video of Bill Gates.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.